In patients with active cancer and venous thromboembolism, whether extended treatment with a reduced dose of an oral anticoagulant ... a 1:1 ratio to receive oral apixaban at a reduced (2.5 ...

API-CAT establishes reduced-dose apixaban "as an appropriate regimen" for anticoagulation ... trial demonstrate lower rates of clinically relevant bleeding in the half-dose DOAC arm than the full-dose ...

CHICAGO — Extended therapy with reduced-dose apixaban is just as effective as the high dose in preventing recurrent venous thromboembolism (VTE) in patients with active cancer who completed at ...

CHICAGO, IL—For patients with active cancer who’ve had venous thromboembolism (VTE), 12-month extended anticoagulation with reduced-dose apixaban is noninferior to the full dose at preventing ...

The aim of the API-CAT trial was to assess whether the lower dose of apixaban was comparable to the full dose in preventing VTE recurrence in patients with active cancer who had completed at least ...

the full-dose group) of apixaban for an additional 12 months. Neither patients nor their doctors knew which dose patients were receiving until the end of the trial. All deaths, suspected VTE ...

Results show noninferiority to a full dose in preventing a recurrence of blood clots and an advantage when it comes to bleeding risks.

It has a plasma elimination half-life of 12 hours and has been ... without the need for anticoagulation monitoring or dosage adjustment. Apixaban has multiple elimination pathways, and its ...